# Lion TCR

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lion-tcr

- Industry: Biotechnology
- Headquarters: Singapore, Singapore
- Website: www.liontcr.com/
- Total disclosed funding: $72M
- Latest round: Series B (Jan 25, 2026)
- Investors on record: 11

## About

Founded in 2016 and based in Singapore, Lion TCR Pte. Ltd., trading as Lion TCR, is a biotechnology company dedicated to the development and commercialization of our TCR-T therapy. In November 2022, it announces a Poster Presentation of the Phase 1 Study for LioCyx-M at AASLD The Liver Meeting. Xiaoming Peng is the CEO of the company, graduated from the National University of Singapore, and has over 18 years of working experience at A*STAR. In January 2026, Lion TCR raised a series B+ funding from Wanlian Tianze and Wanlian Securities.

Lion TCR uses TCR-T cells for clinical trials against liver cancer to evaluate the safety and effectiveness of TCR-T cell therapy in clinical practice. The company has developed an autologous T-cell product LioCyx-M which is transferred with mRNA encoding HBV antigen-specific TCR, and it has been used clinically for the treatment of HBV-related liver cancer and recurrent HBV-related liver cancer post-liver transplant.

The company's revenue is generated by conducting ongoing clinical trials against hepatocellular carcinoma.

## Funding rounds

- Series B, Jan 25, 2026 — Wanlian Tianze, Wanlian Securities
- Series B, Jun 27, 2023, $40M — Guangzhou Guoju Venture Capital, Guangzhou Industry Investment Holding Group, Shanghai Shifeng Xinhui Venture Capital Management
- Series B, Jan 16, 2023, $11M — Westlake Ventures, V Star Capital, Smartech, CSPC NBP Pharmaceutical, Chapman Technology Co. Ltd
- Series A, Apr 16, 2018, $21M — ABC Capital, Westlake Ventures, Smartech, Chapman Technology Co. Ltd

## Investors

- ABC Capital (https://capitalatlas.ai/funds/abc-capital) — Series A
- Westlake Ventures (https://capitalatlas.ai/funds/westlake-ventures) — Series A, Series B
- Smartech — Series A, Series B
- Chapman Technology Co. Ltd — Series A, Series B
- V Star Capital (https://capitalatlas.ai/funds/v-star-capital) — Series B
- CSPC NBP Pharmaceutical — Series B
- Guangzhou Guoju Venture Capital (https://capitalatlas.ai/funds/guangzhou-guoju-venture-capital) — Series B
- Guangzhou Industry Investment Holding Group (https://capitalatlas.ai/funds/guangzhou-industry-investment-holding-group) — Series B
- Shanghai Shifeng Xinhui Venture Capital Management — Series B
- Wanlian Tianze (https://capitalatlas.ai/funds/wanlian-tianze) — Series B
- Wanlian Securities — Series B